{"id":292422,"date":"2026-10-07T13:31:43","date_gmt":"2026-10-07T08:01:43","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=292422"},"modified":"2026-10-07T13:31:43","modified_gmt":"2026-10-07T08:01:43","slug":"why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/","title":{"rendered":"Jenburkt Pharmaceuticals Ltd. (JENBURPH) 52 Week Low Streak: Second Straight Session Near the Yearly Low"},"content":{"rendered":"<div class=\"univest-blue-summary\" style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:12px 16px;margin:0 0 18px 0;font-style:italic;\"><em><a href=\"https:\/\/univest.in\/stocks\/jenburph\/jenburkt-pharmaceuticals-ltd-share-price-today\">Jenburkt Pharmaceuticals Ltd. (JENBURPH)<\/a> share price is trading within 2% of its 52-week low today and stood at Rs 892.15, down 1.42% from the previous close. Market cap was Rs 399.4 crore.<\/em><\/div>\n<p style=\"margin-top:0!important;\">Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak has now extended to a second straight session, with the stock trading near its 52-week low again at Rs 892.15. Across the streak, the share price has moved down 0.87%, and the latest Univest data confirms the repeated near-low pattern without establishing any company-specific cause for the continued weakness.<\/p>\n<p>Jenburkt Pharmaceuticals Ltd. share price was at Rs 905 at the previous close, opened at Rs 905, touched a high of Rs 905 and a low of Rs 892.15 during the period covered here. The company\u2019s market capitalisation stood at Rs 399.4 crore. For readers, the significance lies less in one session alone and more in the repeated trading near the yearly low, which signals that the stock is spending more time around that support area than a single-day move would suggest.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Jenburkt_Pharmaceuticals_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\" title=\"Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak: Consecutive Low Analysis\">Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#What_the_Repeated_52-Week_Lows_Show\" title=\"What the Repeated 52-Week Lows Show\">What the Repeated 52-Week Lows Show<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Jenburkt_Pharmaceuticals_Ltd_JENBURPH_Fundamental_Analysis\" title=\"Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis\">Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Sector_and_Industry_Context\" title=\"Sector and Industry Context\">Sector and Industry Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Peer_Comparison\" title=\"Peer Comparison\">Peer Comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Why_Investors_Are_Watching\" title=\"Why Investors Are Watching\">Why Investors Are Watching<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#About_the_Company\" title=\"About the Company\">About the Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#How_many_sessions_has_Jenburkt_Pharmaceuticals_Ltd_traded_near_its_52-week_low\" title=\"How many sessions has Jenburkt Pharmaceuticals Ltd. traded near its 52-week low?\">How many sessions has Jenburkt Pharmaceuticals Ltd. traded near its 52-week low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#What_is_the_cumulative_move_across_the_streak\" title=\"What is the cumulative move across the streak?\">What is the cumulative move across the streak?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Does_the_data_confirm_why_the_stock_is_staying_weak\" title=\"Does the data confirm why the stock is staying weak?\">Does the data confirm why the stock is staying weak?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#How_did_Jenburkt_Pharmaceuticals_Ltd_trade_in_the_latest_move\" title=\"How did Jenburkt Pharmaceuticals Ltd. trade in the latest move?\">How did Jenburkt Pharmaceuticals Ltd. trade in the latest move?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Is_Jenburkt_Pharmaceuticals_Ltd_expensive_on_valuation\" title=\"Is Jenburkt Pharmaceuticals Ltd. expensive on valuation?\">Is Jenburkt Pharmaceuticals Ltd. expensive on valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#How_do_profitability_ratios_look_in_Jenburkt_Pharmaceuticals_Ltd_Stock_Analysis\" title=\"How do profitability ratios look in Jenburkt Pharmaceuticals Ltd. Stock Analysis?\">How do profitability ratios look in Jenburkt Pharmaceuticals Ltd. Stock Analysis?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#How_does_Jenburkt_Pharmaceuticals_Ltd_compare_with_peers_in_the_same_industry\" title=\"How does Jenburkt Pharmaceuticals Ltd. compare with peers in the same industry?\">How does Jenburkt Pharmaceuticals Ltd. compare with peers in the same industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#What_should_investors_monitor_next\" title=\"What should investors monitor next?\">What should investors monitor next?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/why-jenburkt-pharmaceuticals-ltd-share-near-52-week-consecutive-low-2026\/#Track_Jenburkt_Pharmaceuticals_Ltd_JENBURPH_Share_Price_on_Univest\" title=\"Track Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price on Univest\">Track Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price on Univest<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Jenburkt_Pharmaceuticals_Ltd_52_Week_Low_Streak_Consecutive_Low_Analysis\"><\/span><strong>Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak: Consecutive Low Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Current Price<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 892.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Previous Close<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 905<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Today&#39;s Move<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs -12.85 (-1.42%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Open<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 905<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>High<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 905<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Low<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 892.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 399.4 crore<\/td>\n<\/tr>\n<\/table>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) traded at Rs 892.15 versus the previous close of Rs 905, a fall of 1.42%. The stock opened at Rs 905, reached a high of Rs 905, touched a low of Rs 892.15.<\/p>\n<p>Jenburkt Pharmaceuticals Ltd. Share Price Today remained under pressure as the stock was at Rs 892.15, lower than the previous close of Rs 905 by Rs 12.85 or 1.42%. The stock opened at Rs 905 and touched the same level as its intraperiod high before slipping to Rs 892.15, which also marked the low for the move discussed here. That range shows that the price weakened after a flat start and stayed close to the lower end of the band.<\/p>\n<p>For a stock in a near 52-week low streak, this kind of price action matters because it keeps the market focused on whether the current yearly low is holding or whether the decline remains active. Jenburkt Pharmaceuticals Ltd. Share Price has therefore stayed in a narrow and weak range, with the market capitalisation at Rs 399.4 crore adding a size context that helps readers place the move in perspective. The broader message from today\u2019s trading is simple: the stock is still trading near the yearly low, and the repeated pattern deserves attention on the next few sessions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Repeated_52-Week_Lows_Show\"><\/span><strong>What the Repeated 52-Week Lows Show<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak is important because it highlights persistence rather than one isolated fall. The stock has traded within 2% of its 52-week low for a second straight session, and that back-to-back pattern is what makes the move notable. The cumulative change across the streak is down 0.87%, which is modest in percentage terms but still enough to show that the stock has not meaningfully moved away from the yearly trough.<\/p>\n<p>The latest Univest data confirms the repeated near-low pattern, but it does not establish a company-specific cause for the continued decline. That matters for interpretation. A repeated low can reflect broader sentiment, a lack of near-term price support, or simply an extended weak phase in trading, but none of those explanations should be assumed without direct evidence. For investors searching Jenburkt Pharmaceuticals Ltd. Stock News or Jenburkt Pharmaceuticals Ltd. Share Price Update, the key takeaway is that the stock is not just briefly touching the lower zone; it is staying there.<\/p>\n<p>In practical terms, Jenburkt Pharmaceuticals Ltd. Consecutive 52 Week Low behaviour keeps the yearly low in focus as the immediate reference point. The stock has now spent two sessions near that boundary, which makes the next directional move more important than the one just recorded. If the price stays trapped near the trough, the streak remains intact; if it starts trading higher and holds above the near-low zone, the pattern begins to lose intensity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jenburkt_Pharmaceuticals_Ltd_JENBURPH_Fundamental_Analysis\"><\/span><strong>Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 399.4 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">12.17x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">1.97x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.84%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">25.34%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 74.39<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Book Value Per Share<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 459.8<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.29%<\/td>\n<\/tr>\n<\/table>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) fundamental metrics show P\/E 12.17x, P\/B 1.97x, ROE 18.84%, ROCE 25.34%. These figures provide context only and are not a buy or sell signal.<\/p>\n<p>Jenburkt Pharmaceuticals Ltd. has a market capitalisation of Rs 399.4 crore, which gives readers a sense of company size before judging valuation. On valuation, P\/E at 12.17x, P\/B at 1.97x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.84% and ROCE of 25.34%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 74.39, book value per share of Rs 459.8, dividend yield of 2.29%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P\/E of 28.4x, median ROE of 11.61%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Pharmaceuticals &amp; Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">12.17x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">28.4x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">41.29x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0x to 695.67x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">1.97x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.9x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">18.84%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">11.61%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">25.34%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">13.46%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 399.4 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 833.16 crore<\/td>\n<\/tr>\n<\/table>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) is classified under sector: Healthcare and industry: Pharmaceuticals &amp; Drugs.<\/p>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P\/E ratio of 12.17x, which is below the benchmark median of 28.4x, a difference of -57.15%. P\/E is a valuation multiple and is not, by itself, a buy or sell signal.<\/p>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROE of 18.84%, which is above the benchmark median of 11.61%, a difference of +62.27%. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROCE of 25.34%, which is above the benchmark median of 13.46%, a difference of +88.26%.<\/p>\n<p>Track stocks falling to yearly lows through the <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/medicameq\/medicamen-biotech-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Medicamen Biotech Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">MEDICAMEQ<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">418.75<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">39.47<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">1.58<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">3.23<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">5.77<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/astonealab\/astonea-labs-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Astonea Labs Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">ASTONEALAB<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">352.12<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">77.75<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">6.14<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">11.95<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">10.51<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/tll\/trident-lifeline-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Trident Lifeline Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">TLL<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">465.25<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">24.79<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">4.79<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">18.78<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">19.17<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/haleoslabs\/sms-lifesciences-india-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>SMS Lifesciences India Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">HALEOSLABS<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">468.31<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">30.34<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2.23<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">8.68<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">10.53<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/albertdavd\/albert-david-ltd-share-price-today\" style=\"color:#0645AD;text-decoration:underline;\"><strong>Albert David Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">ALBERTDAVD<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">474.27<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">21.02<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">1.12<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-0.38<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">0.83<\/td>\n<\/tr>\n<\/table>\n<p>Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P\/E ratio of 12.17x compared with the displayed peer median of 30.34x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.84% compares with a peer median of 8.68% across the companies shown in the table. ROCE stood at 25.34% versus the displayed peer median of 10.51%, providing a capital-efficiency comparison. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a market capitalisation of Rs 399.4 crore. Among the 5 peers shown, 4 have a larger market capitalisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching\"><\/span><strong>Why Investors Are Watching<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak has extended to a second straight session, keeping the yearly low in focus.<\/li>\n<li>The cumulative move across the streak is down 0.87%, which confirms persistent weakness rather than a one-day dip.<\/li>\n<li>Jenburkt Pharmaceuticals Ltd. Share Price is trading below the previous close and remains close to the lower end of the recent range.<\/li>\n<li>Jenburkt Pharmaceuticals Ltd. Fundamental Analysis shows P\/E, P\/B, ROE and ROCE that are useful context points against the peer set.<\/li>\n<li>Investors watching Jenburkt Pharmaceuticals Ltd. Stock News will likely monitor whether the stock continues to trade near the 52-week trough or begins to move away from it.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"About_the_Company\"><\/span><strong>About the Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jenburkt Pharmaceuticals Ltd. is part of the Pharmaceuticals &#038; Drugs industry within the Healthcare sector. The company\u2019s current market capitalisation is Rs 399.4 crore, placing it among the smaller names in the peer set by value, while the supplied financial ratios give a useful snapshot of earnings power and capital efficiency. For readers following Jenburkt Pharmaceuticals Ltd. Share Price Today, the key point is that the stock combines a near-low trading pattern with a valuation profile that is not obviously stretched versus the industry data provided here.<\/p>\n<p>The company\u2019s profile in this article is therefore best understood through two lenses: its repeated near-52-week-low trading and its operating metrics relative to peers. That combination is what makes the current Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak relevant for Stock News readers, sector watchers and those comparing shares in the healthcare space.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"How_many_sessions_has_Jenburkt_Pharmaceuticals_Ltd_traded_near_its_52-week_low\"><\/span><strong>How many sessions has Jenburkt Pharmaceuticals Ltd. traded near its 52-week low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jenburkt Pharmaceuticals Ltd. has traded within 2% of its 52-week low for a second straight session. That repeated pattern is what defines the current Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_cumulative_move_across_the_streak\"><\/span><strong>What is the cumulative move across the streak?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The cumulative change across the streak is down 0.87%. This is the figure provided for the repeated near-low pattern and should be read as a short streak-based decline, not a full-period performance measure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_the_data_confirm_why_the_stock_is_staying_weak\"><\/span><strong>Does the data confirm why the stock is staying weak?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. The latest Univest data confirms the repeated near-low pattern, but it does not establish a company-specific cause for the continued weakness. Readers should separate the price pattern from any unverified explanation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Jenburkt_Pharmaceuticals_Ltd_trade_in_the_latest_move\"><\/span><strong>How did Jenburkt Pharmaceuticals Ltd. trade in the latest move?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock was at Rs 892.15, compared with a previous close of Rs 905. It opened at Rs 905, touched a high of Rs 905 and a low of Rs 892.15 in the period covered here.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Jenburkt_Pharmaceuticals_Ltd_expensive_on_valuation\"><\/span><strong>Is Jenburkt Pharmaceuticals Ltd. expensive on valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Based on the latest Univest industry comparison, the stock is not expensive on a relative basis. Its P\/E of 12.17 is below the industry median of 28.4, and its P\/B of 1.97 is also below the industry median of 2.9.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_profitability_ratios_look_in_Jenburkt_Pharmaceuticals_Ltd_Stock_Analysis\"><\/span><strong>How do profitability ratios look in Jenburkt Pharmaceuticals Ltd. Stock Analysis?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company\u2019s ROE of 18.84% and ROCE of 25.34% are both strong against the industry medians shown in the data. That gives Jenburkt Pharmaceuticals Ltd. a comparatively healthier return profile than several peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Jenburkt_Pharmaceuticals_Ltd_compare_with_peers_in_the_same_industry\"><\/span><strong>How does Jenburkt Pharmaceuticals Ltd. compare with peers in the same industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It trades at a lower P\/E than several peers such as Trident Lifeline Ltd., SMS Lifesciences India Ltd. and Astonea Labs Ltd. It also shows stronger return ratios than many of those names in the latest Univest peer set.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_monitor_next\"><\/span><strong>What should investors monitor next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should monitor whether Jenburkt Pharmaceuticals Ltd. Share Price continues to trade near the yearly low or starts to move away from that zone. The repeated-low pattern is the key signal to watch in the next sessions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Track_Jenburkt_Pharmaceuticals_Ltd_JENBURPH_Share_Price_on_Univest\"><\/span><strong>Track Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/jenburph\/jenburkt-pharmaceuticals-ltd-share-price-today\">Jenburkt Pharmaceuticals Ltd. (JENBURPH) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/52-week-low\">Univest 52-week-low screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, yearly-low lists and related market analysis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jenburkt Pharmaceuticals Ltd. Share Price trades near its 52-week low at Rs 892.15, marking a 1.42% decline today. Market cap stands at Rs 399.4 crore.<\/p>\n","protected":false},"author":38,"featured_media":292420,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-292422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["292420"],"rank_math_title":["Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak Analysis"],"rank_math_description":["Jenburkt Pharmaceuticals Ltd. has traded within 2% of its 52-week low for a second straight session. Read the price action, valuation and sector context."],"rank_math_focus_keyword":["Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/jenburkt-pharmaceuticals-ltd-jenburph-52-week-low-streak-second-straight-session.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/292422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=292422"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/292422\/revisions"}],"predecessor-version":[{"id":292424,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/292422\/revisions\/292424"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/292420"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=292422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=292422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=292422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}